Thursday, March 14, 2013
Despite the well-established role of WNT
signaling in many cancers, the pathway has proven difficult to modulate therapeutically
because it is largely composed of hard-to-target protein-protein interactions.
Now, a Boston-based team and a group led by Roche's
unit have each identified a new kinase regulator of WNT signaling-YES1
respectively-that provide two new druggable targets in the pathway.1,2
YES gets a nod
RIP-ping into WNT
Kotz, J. SciBX 6(10); doi:10.1038/scibx.2013.231
Published online March 14, 2013
1. Rosenbluh, J. et al.
Cell; published online Dec. 13, 2012; doi:10.1016/j.cell.2012.11.026
Contact: William C. Hahn, Dana-Farber Cancer Institute, Boston, Mass.
2. Huang, X. et al.
Science; published online Jan. 31, 2013; doi:10.1126/science.1232253
Contact: Vishva M. Dixit, Genentech Inc., South San
3. Seshagiri, S. et al.
Nature 488, 660-664 (2012)
AND INSTITUTIONS MENTIONED
(Xetra:BAYN), Leverkusen, Germany
Blueprint Medicines, Cambridge, Mass.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Broad Institute of MIT and Harvard, Boston, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
Genentech Inc., South San Francisco, Calif.
OncoMed Pharmaceuticals Inc., Redwood City, Calif.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Structural Genomics Consortium, Oxford, U.K.
University of Oxford, Oxford, U.K.